Dr. Ankit Mangla

Hematology
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
Offers Telehealth
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 
OverviewInsuranceLocationsClinical Research

Overview

Ankit Mangla is a Hematologist in Cleveland, Ohio. Dr. Mangla is rated as an Experienced provider by MediFind in the treatment of Triosephosphate Isomerase Deficiency. His top areas of expertise are Essential Thrombocythemia, Classical Hodgkin Lymphoma, Thrombocytopenia, and Immune Thrombocytopenic Purpura (ITP).

His clinical research consists of co-authoring 60 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in IL
Hospital Affiliations
Uh Cleveland Medical Center
University Hospitals Portage Medical Center
Parma Community General Hospital
Uh St John Medical Center
Lake Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

UNIVERSITY HOSPITALS MEDICAL GROUP INC
11100 Euclid Ave, Cleveland, OH 44106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids
A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

60 Total Publications

Is Ultrasound-Based Imaging Essential for Melanoma Active Surveillance?
Is Ultrasound-Based Imaging Essential for Melanoma Active Surveillance?
Journal: Annals of surgical oncology
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mangla's expertise for a condition
ConditionClose
        View All 39 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile